Personalis Reports Second Quarter 2024 Financial Results

Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL) reported strong financial results for Q2 2024, with total revenue increasing 35% year-over-year to $22.6 million. The growth was primarily driven by a 117% increase in revenue from pharma testing and services, reaching $13.2 million. Enterprise customer revenue grew 8% to $8.0 million. The company highlighted clinical performance of NeXT Personal® at ASCO, demonstrating early cancer recurrence detection and therapy response prediction.

Personalis delivered 561 molecular tests in Q2, a 66% increase from the previous quarter. The company also announced cross-license agreements and settled an IP lawsuit. Despite revenue growth, Personalis reported a net loss of $12.8 million, a 47% improvement year-over-year. The company raised its full-year 2024 revenue guidance to $79.0-$81.0 million and expects Q3 2024 revenue between $21.0-$22.0 million.

Positive

• Total revenue increased 35% year-over-year to $22.6 million in Q2 2024
• Revenue from pharma testing and services grew 117% to $13.2 million
• Delivered 561 molecular tests in Q2, a 66% increase from the previous quarter
• Net loss decreased by 47% year-over-year to $12.8 million
• Raised full-year 2024 revenue guidance to $79.0-$81.0 million
• Cash, cash equivalents, and short-term investments of $87.0 million as of June 30, 2024

Negative

• Revenue from population sequencing for the VA Million Veterans Program decreased 57% to $1.3 million
• Company still operating at a net loss of $12.8 million in Q2 2024
• Projected non-GAAP net loss of approximately $75.0 million for full year 2024
• Expected cash usage of approximately $60.0 million for full year 2024

Insights

Financial Analyst

Personalis' Q2 2024 results show strong revenue growth of 35% year-over-year, reaching $22.6 million. The standout performer was pharma testing and services, growing 117% to $13.2 million. This surge indicates increasing market traction for their advanced genomics solutions in precision oncology.

The company's improved financial position is evident from the reduced net loss of $12.8 million, down 47% from last year. With $87 million in cash and equivalents, Personalis has a solid runway for future growth. The raised full-year revenue guidance to $79-$81 million reflects management's confidence in continued momentum.

However, investors should note the 57% decline in revenue from the Veterans Affairs program, highlighting the need to diversify revenue streams. The focus on the 'Win-in-MRD' strategy and recent patent settlements could be key drivers for future growth and market positioning.

Oncology Researcher

The clinical performance data of NeXT Personal® presented at ASCO is highly promising. Detecting cancer recurrence 15 months before imaging in breast cancer patients demonstrates significant potential for early intervention. The 100% detection rate and specificity are remarkable, potentially positioning NeXT Personal as a game-changer in cancer monitoring.

Furthermore, the ability to predict therapy response and clinical outcomes in late-stage cancer patients receiving immunotherapy, with an average of 81 days earlier detection than imaging, could revolutionize treatment strategies. These results suggest NeXT Personal could become an essential tool in personalized cancer care, potentially improving patient outcomes and reducing healthcare costs.

The 66% increase in molecular tests delivered indicates growing clinical adoption, which could accelerate with potential Medicare coverage. This technology's impact on patient care could drive substantial market growth for Personalis.

Legal Expert

The recent legal developments for Personalis are strategically significant. The cross-license agreement with Myriad Genetics and the settlement with Foresight Diagnostics strengthen Personalis' intellectual property position in the important minimal residual disease (MRD) detection space. These agreements not only mitigate legal risks but also potentially open new revenue streams through licensing.

The resolution of these IP challenges clears a path for Personalis to focus on commercialization and market expansion of its MRD technologies. This could be particularly important as the company pursues its 'Win-in-MRD' strategy. The legal clarity may also make Personalis more attractive to potential partners or investors in the precision oncology field.

However, investors should monitor ongoing patent landscapes in this rapidly evolving sector, as further legal challenges could arise as the MRD market grows more competitive.

Strong Revenue Growth of 35% Year-over-Year Driven by 117% Growth from Biopharma Business

Raises 2024 Full Year Revenue Guidance

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2024, and provided recent business accomplishments.

Recent Business Accomplishments

• Highlighted clinical performance of NeXT Personal® at the American Society of Clinical Oncology (ASCO) meeting in May
  • Compelling breast cancer detection results were presented by Dr. Isaac Garcia-Murillas (Institute of Cancer Research, London) and Prof. Nicolas Turner (Royal Marsden NHS Foundation Trust UK). In this study, they found:
    • NeXT Personal detected cancer recurrence approximately 15 months before imaging
    • 100% of patients that recurred were detected with NeXT Personal and 100% of patients that were ctDNA negative were cancer-free at follow up time points
  • A presentation by Dr. Rodrigo Toledo of the Vall d’Hebron Institute of Oncology highlighted the importance of NeXT Personal’s use for immunotherapy monitoring. This data showed:
    • Baseline levels of ctDNA and the changes detected by NeXT Personal predict therapy response and clinical outcomes for late-stage cancer patients receiving immunotherapy
    • NeXT Personal detected cancer progression 81 days before imaging on average
• Delivered 561 total molecular tests in the second quarter of 2024, a 66% increase compared with the prior quarter, and commenced NeXT Personal Dx commercialization efforts with Tempus AI, Inc. (Tempus)
• Announced a cross-license agreement with Myriad Genetics, Inc. covering patent estates for tumor-informed approaches to detect minimal residual disease (MRD)
• Successfully settled the IP lawsuit with Foresight Diagnostics, Inc. (Foresight) with Foresight agreeing to license Personalis’ MRD patents

Second Quarter 2024 Results Compared to Second Quarter 2023

• Reported total company revenue of $22.6 million in the second quarter of 2024, an increase of 35% compared with $16.7 million
  • Revenue from pharma testing and services of $13.2 million in the second quarter of 2024, an increase of 117% compared with $6.1 million
  • Revenue from Enterprise customers of $8.0 million in the second quarter of 2024, an increase of 8% compared with $7.4 million
  • Revenue from population sequencing for the U.S. Department of Veterans Affairs Million Veterans Program of $1.3 million in the second quarter of 2024, a decrease of 57% compared with $3.0 million
• Other Income of $3.0 million in the second quarter of 2024, which consists of a non-cash gain of $3.0 million related to fair-value accounting for the outstanding warrants issued to Tempus
• Net loss of $12.8 million in the second quarter of 2024, a decrease of 47% compared with $24.0 million
• Cash, cash equivalents, and short-term investments of $87.0 million as of June 30, 2024

“The revenue growth depicts growing customer confidence in both our technology and platform. Importantly, the growth in our clinical testing volume means that we can see the impact on patient lives. Now that our collaborators have presented compelling NeXT Personal clinical evidence, we expect to leverage that towards obtaining Medicare coverage and materially increasing the number of patients we can help,” said Chris Hall, Chief Executive Officer at Personalis. “As we continue to execute on our Win-in-MRD strategy, we are more confident than ever in our ability to drive broad adoption for patient testing.”

Third Quarter and Revised Full Year 2024 Outlook

Personalis expects the following for the third quarter of 2024:

• Total company revenue in the range of $21.0 to $22.0 million
• Revenue from pharma tests, enterprise sales, and other customers in the range of $17.0 to $18.0 million
• Revenue from population sequencing of approximately $4.0 million

Personalis expects the following for the full year of 2024:

• Total company revenue in the range of $79.0 to $81.0 million, an increase from $76.0 to $78.0 million
• Revenue from pharma tests, enterprise sales, and all other customers in the range of $71.0 to $73.0 million, an increase from prior guidance of $68.0 to $70.0 million
• Revenue from population sequencing of approximately $8.0 million
• Non-GAAP net loss of approximately $75.0 million, a decrease from our prior guidance of $77.0 million and excludes any non-cash gain or loss from the outstanding warrants issued to Tempus
• Cash usage of approximately $60.0 million, a decrease from our prior guidance of $62.0 million

Webcast and Conference Call Information

Personalis will host a conference call to discuss the second quarter of 2024 financial results, as well as plans for 2024, after market close on Wednesday, August 7, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live by dialing 800-717-1738 for domestic callers or 646-307-1865 for international callers. The live webinar can be accessed at https://investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Non-GAAP Financial Measure

To supplement our financial guidance presented in accordance with GAAP, we are presenting expected non-GAAP net loss for the full year ending December 31, 2024, which excludes income and expense from the outstanding warrants issued to Tempus from GAAP net loss. We are excluding income and expense attributable to the fair value of the outstanding warrants issued to Tempus because they are non-cash financial measures that require remeasurement of the fair value, derived from the then-current trading price of our Common Stock, as of each reporting date, and consequently there is substantial uncertainty associated with forecasting the fair value of the Tempus warrants at the future measurement dates. For this reason, we have not provided a reconciliation of our forward-looking non-GAAP net loss to GAAP net loss (the most directly comparable GAAP financial measure), in reliance on the “unreasonable efforts” exception set forth in the applicable regulations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “anticipate,” “estimate,” “expect,” “if,” “may,” “future,” “will” or similar expressions. These statements include statements relating to: Personalis’ third quarter and full year 2024 outlook for revenue, non-GAAP net loss, and cash usage, the attributes, advantages or clinical validity of the NeXT Personal Dx test, broad adoption of the NeXT Personal Dx test for patient testing and the benefits to patients from use of the same, and Personalis’ obtaining Medicare coverage. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the timing and pace of new orders from customers, including from Natera and the U.S. Department of Veterans Affairs Million Veterans Program; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; Personalis’ ability to demonstrate attributes, advantages or clinical validity of the NeXT Personal Dx test, the rate of adoption of the NeXT Personal Dx test, Personalis’ ability to obtain Medicare coverage and reimbursement, Personalis’ achievement of milestones set forth in the collaboration and co-commercialization agreement with Tempus, the success of Personalis’ clinical sales team and Tempus’ sales and marketing efforts, the expected benefits or success of Personalis’ relationships with research collaborators, the impact of Personalis’ abstract presentations at the American Society of Clinical Oncology medical conference in May, and the adoption and use of the NeXT Personal Dx test by oncologists. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on February 28, 2024, as updated by Personalis’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 8, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, being filed with the SEC today. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

PERSONALIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data)
		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Revenue		$	22,580			$	16,699			$	42,105			$	35,559
Costs and expenses
Cost of revenue			14,543				11,907				28,575				26,037
Research and development			12,957				17,852				25,728				34,425
Selling, general and administrative			11,973				12,134				23,575				26,231
Restructuring and other charges			—				152				—				4,037
Total costs and expenses			39,473				42,045				77,878				90,730
Loss from operations			(16,893	)			(25,346	)			(35,773	)			(55,171	)
Interest income			1,136				1,465				2,495				2,718
Interest expense			(9	)			(39	)			(18	)			(86	)
Other income (expense), net			2,968				1				7,537				(25	)
Loss before income taxes			(12,798	)			(23,919	)			(25,759	)			(52,564	)
Provision for income taxes			4				36				11				50
Net loss		$	(12,802	)		$	(23,955	)		$	(25,770	)		$	(52,614	)
Net loss per share, basic and diluted		$	(0.24	)		$	(0.50	)		$	(0.50	)		$	(1.11	)
Weighted-average shares outstanding, basic and diluted			52,394,678				47,669,513				51,536,632				47,204,891

PERSONALIS, INC. SUPPLEMENTAL REVENUE INFORMATION (unaudited) (in thousands)
		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Pharma tests and services		$	13,197			$	6,083			$	23,009			$	12,416
Enterprise sales			7,958				7,386				15,930				16,844
Population sequencing			1,280				3,000				2,780				6,005
Other			145				230				386				294
Total revenue		$	22,580			$	16,699			$	42,105			$	35,559

PERSONALIS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands, except share and per share data)
		June 30, 2024				December 31, 2023
Assets
Current assets
Cash and cash equivalents		$	47,747			$	56,984
Short-term investments			39,225				57,195
Accounts receivable, net			12,921				17,730
Inventory and other deferred costs			9,164				10,474
Prepaid expenses and other current assets			4,046				4,361
Total current assets			113,103				146,744
Property and equipment, net			52,662				57,366
Operating lease right-of-use assets			17,166				17,852
Other long-term assets			2,571				3,137
Total assets		$	185,502			$	225,099
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable		$	9,936			$	14,920
Accrued and other current liabilities			19,248				23,941
Contract liabilities			4,174				3,288
Short-term warrant liability			775				5,085
Total current liabilities			34,133				47,234
Long-term operating lease liabilities			36,524				38,321
Long-term warrant liability			1,513				4,942
Other long-term liabilities			1,060				5,161
Total liabilities			73,230				95,658
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued			—				—
Common stock, $0.0001 par value — 200,000,000 shares authorized; 53,052,847 and 50,480,694 shares issued and outstanding, respectively			5				5
Additional paid-in capital			606,863				598,364
Accumulated other comprehensive loss			(120	)			(222	)
Accumulated deficit			(494,476	)			(468,706	)
Total stockholders’ equity			112,272				129,441
Total liabilities and stockholders’ equity		$	185,502			$	225,099

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807799344/en/

Investor Relations Contact:

Caroline Corner

investors@personalis.com

646-277-1279

Media:

pr@personalis.com

Source: Personalis, Inc.

FAQ

What was Personalis' (PSNL) revenue growth in Q2 2024?

Personalis reported a 35% year-over-year increase in total revenue, reaching $22.6 million in Q2 2024.

How much did Personalis' (PSNL) pharma testing and services revenue grow in Q2 2024?

Personalis' revenue from pharma testing and services grew by 117% year-over-year, reaching $13.2 million in Q2 2024.

What was Personalis' (PSNL) net loss in Q2 2024?

Personalis reported a net loss of $12.8 million in Q2 2024, which is a 47% improvement compared to the same period in 2023.

What is Personalis' (PSNL) revised full-year revenue guidance for 2024?

Personalis raised its full-year 2024 revenue guidance to a range of $79.0 to $81.0 million.

How many molecular tests did Personalis (PSNL) deliver in Q2 2024?

Personalis delivered 561 total molecular tests in Q2 2024, representing a 66% increase compared to the previous quarter.